FATE Q3 2025 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-43.4% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$35M-1995.1% margin

Net Income

-$32M-1852.4% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-8.7%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$27M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$344M

Total Liabilities

$110M

Stockholders' Equity

$234M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$3M	-43.4%
Gross Profit	$2M	$3M	-43.4%
Operating Income	-$35M	-$52M	+33.7%
Net Income	-$32M	-$48M	+32.4%